Lopez Varela [37] | 2019 | Mexico | 974 | ≥40 years of age and ≥10 pack-years, or ≥50 pipes per year or ≥50 cigars per year and/or exposure to biomass smoke | PUMA | ≥5 | 85.4 | 37.6 | 0.70 |
Fujita [38] | 2020 | Japan | 1001 | No previous diagnosis of asthma, TB and lung cancer | Changed CDQ | ≥18 | 81.6 | 59.7 | 0.73 |
Ronaldson [30] | 2018 | UK | 216 | ≥35 years of age and current smokers | COPD-PS | Standard scoring criteria | 53.3 | 78.6 | 0.66 |
| | | | | CDQ | Standard scoring criteria | 81.5 | 52.3 | 0.67 |
Spyratos [28] | 2017 | Greece | 3234 | >40 years of age and ≥10 pack-years | CDQ | ≥17 | 74 | 72 | 0.80 |
| | | | | COPD-PS | ≥5 | 56 | 90 | 0.79 |
| | | | | LFQ | ≤18 | 79 | 68 | 0.81 |
Weiss [31] | 2017 | Austria | 775 | ≥40 years of age | SCSQ | ≥2 | 67.1 | 58.9 | 0.66 |
Demirci [40] | 2017 | Turkey | 357 | 40–65 years of age, with no previous history of obstructive lung disease | CAT | ≥11 | 66.7 | 75.2 | NA |
Sogbetun [27] | 2016 | USA | 376 | No limitation | VAFOSQ | ≥25 | 66 | 43 | 0.58 |
| | | 255 | No limitation | 11-Q | ≥5 | 94 | 9 | 0.61 |
| | | 362 | No limitation | COPD-PS | ≥5 | 69 | 46 | 0.62 |
| | | 376 | No limitation | LFQ | ≤18 | 95 | 14 | 0.66 |
| | | 336 | No limitation | Personal level screener COPD | Questionnaire algorithm | 50 | 69 | 0.59 |
Lopez Varela [32] | 2016 | Argentina, Colombia, Venezuela, Uruguay | 1540 | ≥40 years of age and ≥10 pack-years, or ≥50 pipes per year or ≥50 cigars per year and/or exposure to | PUMA | ≥25 (weighted) | 76.3 | 69.3 | 0.79 |
| | | | biomass smoke | | ≥5 (simple) | 74.2 | 64.8 | 0.76 |
Sogbetun [46] | 2016 | USA | 278 | All patients with a previously scheduled office visit | VAFOSQ (retrospective validation) | ≥25 | 59.9 | 69.8 | 0.72 |
Llordes [47] | 2017 | Spain | 407 | ≥40 years of age and ≥1 pack-year, with no | EGARPOC | 13 | 72.9 | 58.3 | 0.68 |
| | | | previous diagnosis of | RHSQ | >17 | 73.8 | 56 | 0.72 |
| | | | COPD | COPD-PS | ≥4 | 80.4 | 47.7 | 0.65 |
| | | | | Two screening questions | Both positive | 59.8 | 51.7 | 0.56 |
Stanley [29] | 2014 | Australia | 1054 | 40–85 years of age and former or current smokers, with no previous diagnosis | CDQ | ≥16.5 | 79.7 | 46.8 | 0.71 |
| | | | of COPD | | ≥19.5 | 63 | 70.1 | |
Cui [35] | 2012 | China | 150 | ≥40 years of age; COPD patients (n=100) and non-COPD patients (n=50) | Discriminant function model | NA | 89 | 82 | NA |
Miravitlles [45] | 2012 | Spain | 173 | Controls: ≥35 years of age and no previous diagnosis of COPD Cases: COPD | COPD-PS (Spanish) | ≥4 | 93.6 | 64.8 | 0.79 |
| | | | stages I and II | | ≥5 | 65.4 | 88 | |
Sichletidis [26] | 2011 | Greece | 1078 | ≥40 years of age and no previous diagnosis of COPD | CDQ | ≥17 | 80 | 95 | NA |
Frith [43] | 2011 | Australia | 204 | ≥50 years of age, smoker/ex-smoker and no previous diagnosis of obstructive | CDQ | ≥16.5 | 91 | 37 | 0.72 |
| | | | lung disease | | ≥19.5 | 71 | 62 | |
Kotz [36] | 2008 | The Netherlands | 676 | 40–70 years of age and >10 pack-years, with respiratory symptoms and no previous | CDQ | ≥16.5 | 89.2 | 24.4 | 0.65 |
| | | | respiratory diagnosis | | ≥19.5 | 65.8 | 54.0 | |
Price [41] | 2006 | UK, USA | 246 | ≥40 years of age and smokers, with no previous respiratory | CDQ | ≥16.5 | 58.7 | 77 | 0.82 |
| | | | diagnosis | | ≥19.5 | 80.4 | 57.5 | |